These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 9683774)

  • 1. Decrease in the level and mRNA expression of LH-RH and EGF receptors after treatment with LH-RH antagonist cetrorelix in DU-145 prostate tumor xenografts in nude mice.
    Lamharzi N; Halmos G; Jungwirth A; Schally AV
    Int J Oncol; 1998 Sep; 13(3):429-35. PubMed ID: 9683774
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of growth of androgen-independent DU-145 prostate cancer in vivo by luteinising hormone-releasing hormone antagonist Cetrorelix and bombesin antagonists RC-3940-II and RC-3950-II.
    Jungwirth A; Pinski J; Galvan G; Halmos G; Szepeshazi K; Cai RZ; Groot K; Vadillo-Buenfil M; Schally AV
    Eur J Cancer; 1997 Jun; 33(7):1141-8. PubMed ID: 9376196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Down-regulation and change in subcellular distribution of receptors for luteinizing hormone-releasing hormone in OV-1063 human epithelial ovarian cancers during therapy with LH-RH antagonist Cetrorelix.
    Halmos G; Schally AV; Kahan Z
    Int J Oncol; 2000 Aug; 17(2):367-73. PubMed ID: 10891548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers.
    Letsch M; Schally AV; Szepeshazi K; Halmos G; Nagy A
    Clin Cancer Res; 2003 Oct; 9(12):4505-13. PubMed ID: 14555524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Luteinizing hormone-releasing hormone (LH-RH) antagonist Cetrorelix inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of IGF-II in tumors.
    Lamharzi N; Schally AV; Koppán M
    Regul Pept; 1998 Oct; 77(1-3):185-92. PubMed ID: 9809814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Luteinizing hormone-releasing hormone antagonist Cetrorelix (SB-75) and bombesin antagonist RC-3940-II inhibit the growth of androgen-independent PC-3 prostate cancer in nude mice.
    Jungwirth A; Galvan G; Pinski J; Halmos G; Szepeshazi K; Cai RZ; Groot K; Schally AV
    Prostate; 1997 Aug; 32(3):164-72. PubMed ID: 9254895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic administration of the luteinizing hormone-releasing hormone (LHRH) antagonist cetrorelix decreases gonadotrope responsiveness and pituitary LHRH receptor messenger ribonucleic acid levels in rats.
    Pinski J; Lamharzi N; Halmos G; Groot K; Jungwirth A; Vadillo-Buenfil M; Kakar SS; Schally AV
    Endocrinology; 1996 Aug; 137(8):3430-6. PubMed ID: 8754771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of growth of PC-82 human prostate cancer line xenografts in nude mice by bombesin antagonist RC-3095 or combination of agonist [D-Trp6]-luteinizing hormone-releasing hormone and somatostatin analog RC-160.
    Milovanovic SR; Radulovic S; Groot K; Schally AV
    Prostate; 1992; 20(4):269-80. PubMed ID: 1376910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibitory effects of analogs of luteinizing hormone-releasing hormone on the growth of the androgen-independent Dunning R-3327-AT-1 rat prostate cancer.
    Pinski J; Reile H; Halmos G; Groot K; Schally AV
    Int J Cancer; 1994 Oct; 59(1):51-5. PubMed ID: 7927904
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sustained release formulations of luteinizing hormone-releasing hormone antagonist SB-75 inhibit proliferation and enhance apoptotic cell death of human prostate carcinoma (PC-82) in male nude mice.
    Redding TW; Schally AV; Radulovic S; Milovanovic S; Szepeshazi K; Isaacs JT
    Cancer Res; 1992 May; 52(9):2538-44. PubMed ID: 1568223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Luteinizing hormone-releasing hormone agonist triptorelin and antagonist cetrorelix inhibit EGF-induced c-fos expression in human gynecological cancers.
    Gründker C; Völker P; Schulz KD; Emons G
    Gynecol Oncol; 2000 Aug; 78(2):194-202. PubMed ID: 10926802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of growth of OV-1063 human epithelial ovarian cancer xenografts in nude mice by treatment with luteinizing hormone-releasing hormone antagonist SB-75.
    Yano T; Pinski J; Halmos G; Szepeshazi K; Groot K; Schally AV
    Proc Natl Acad Sci U S A; 1994 Jul; 91(15):7090-4. PubMed ID: 7518926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in subcellular distribution of pituitary receptors for luteinizing hormone-releasing hormone (LH-RH) after treatment with the LH-RH antagonist cetrorelix.
    Halmos G; Schally AV
    Proc Natl Acad Sci U S A; 2002 Jan; 99(2):961-5. PubMed ID: 11805337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of growth of MCF-7 MIII human breast carcinoma in nude mice by treatment with agonists or antagonists of LH-RH.
    Yano T; Korkut E; Pinski J; Szepeshazi K; Milovanovic S; Groot K; Clarke R; Comaru-Schally AM; Schally AV
    Breast Cancer Res Treat; 1992; 21(1):35-45. PubMed ID: 1391973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Growth inhibition of human ovarian cancers by cytotoxic analogues of luteinizing hormone-releasing hormone.
    Miyazaki M; Nagy A; Schally AV; Lamharzi N; Halmos G; Szepeshazi K; Groot K; Armatis P
    J Natl Cancer Inst; 1997 Dec; 89(23):1803-9. PubMed ID: 9392622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of mRNA for luteinizing hormone-releasing hormone receptors and epidermal growth factor receptors in human cancer cell lines.
    Lamharzi N; Halmos G; Armatis P; Schally AV
    Int J Oncol; 1998 Mar; 12(3):671-5. PubMed ID: 9472110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Presence of membrane binding sites for [D-TRP6]-luteinizing hormone-releasing hormone in experimental pancreatic cancer.
    Fekete M; Zalatnai A; Schally AV
    Cancer Lett; 1989 May; 45(2):87-91. PubMed ID: 2567204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Receptors for luteinizing hormone-releasing hormone, somatostatin, prolactin, and epidermal growth factor in rat and human prostate cancers and in benign prostate hyperplasia.
    Fekete M; Redding TW; Comaru-Schally AM; Pontes JE; Connelly RW; Srkalovic G; Schally AV
    Prostate; 1989; 14(3):191-208. PubMed ID: 2471961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of growth of ES-2 human ovarian cancers by bombesin antagonist RC-3095, and luteinizing hormone-releasing hormone antagonist Cetrorelix.
    Chatzistamou I; Schally AV; Szepeshazi K; Groot K; Hebert F; Arencibia JM
    Cancer Lett; 2001 Sep; 171(1):37-45. PubMed ID: 11485826
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Somatostatin analogue RC-160 and LH-RH antagonist SB-75 inhibit growth of MIA PaCa-2 human pancreatic cancer xenografts in nude mice.
    Radulovic S; Comaru-Schally AM; Milovanovic S; Schally AV
    Pancreas; 1993 Jan; 8(1):88-97. PubMed ID: 8093555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.